No results for ‘’
Jubilant Pharmova Ltd
₹1023.85
(0.12%)
Tue, 28 Jul 2026, 04:46 am
Health Technology
Pharmaceuticals: Major
24.5KJubilant Pharmova PE Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 28.49 | 20 | 14.49 | 5.76 | 13.71 | 12.65 | 219.45 | 17.70 | 23.20 | 0 | 16.60 | 21.63 | 20.36 | 18.02 | 4.41 | 12.96 | 14.91 | 0 | 117.13 | 16.90 |
| Price to book ratio | 4.21 | 4.12 | 3.78 | 1.11 | 2.45 | 1.21 | 1.41 | 1.08 | 0.96 | 0.99 | 2.24 | 3.62 | 3.20 | 2.20 | 0.71 | 2.28 | 1.16 | 0.82 | 1.66 | 2.26 |
| Price to sales ratio | 2.52 | 2.52 | 2.33 | 0.46 | 1.53 | 0.85 | 0.75 | 0.53 | 0.44 | 0.42 | 1.14 | 2.15 | 1.76 | 1.15 | 0.66 | 1.78 | 1.01 | 0.71 | 1.35 | 1.96 |
| Price to cash flow ratio | 243.70 | 23.59 | 22.34 | 3.52 | 10.26 | 10.37 | 6.18 | 3.62 | 5.35 | 5.34 | 8.66 | 11.94 | 11.96 | 11.32 | 3.19 | 7.24 | 8.74 | 10.18 | 11.99 | 16.21 |
| Enterprise value | 4314Cr | 5359Cr | 7409Cr | 5160Cr | 8486Cr | 5826Cr | 6802Cr | 6251Cr | 6605Cr | 6827Cr | 10615Cr | 15991Cr | 16256Cr | 13823Cr | 7372Cr | 12995Cr | 8378Cr | 7096Cr | 11725Cr | 15808Cr |
| Enterprise value to EBITDA ratio | 19.94 | 20.47 | 16.01 | 7.65 | 12.75 | 10.61 | 8.14 | 5.98 | 7.02 | 10.46 | 8.40 | 12.37 | 11.18 | 8.09 | 4.64 | 8.91 | 6.94 | 9.33 | 13.08 | 15.17 |
| Debt to equity ratio | 0.88 | 1.82 | 1.68 | 3.06 | 1.45 | 1.81 | 1.69 | 1.52 | 1.67 | 1.95 | 1.51 | 1.18 | 0.85 | 1.01 | 0.86 | 0.60 | 0.60 | 0.68 | 0.67 | 0.44 |
| Return on equity % | 19.50 | 26.33 | 37.04 | 22.44 | 24.38 | 10.53 | 0.66 | 6.43 | 4.26 | -2.27 | 14.46 | 17.98 | 17.09 | 12.92 | 13.02 | 11.10 | 8.23 | -1.14 | 1.42 | 14.36 |
Jubilant Pharmova Ltd Price to Earnings Ratio
The Jubilant Pharmova Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Jubilant Pharmova Ltd's valuation, profitability, and overall financial performance. Tracking the Jubilant Pharmova Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Jubilant Pharmova Ltd (NSE: JUBLPHARMA, BSE: 530019) is currently trading at ₹1023.85, with a market capitalization of ₹16282.51Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Jubilant Pharmova Ltd Price to Earnings Ratio is essential for fundamental analysis.
Jubilant Pharmova Ltd Price to Earnings Ratio Current Value
The current Jubilant Pharmova Ltd Price to Earnings Ratio stands at 16.90.
The Jubilant Pharmova Ltd Price to Earnings Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Jubilant Pharmova Ltd Price to Earnings Ratio Historical Trend
The Jubilant Pharmova Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 16.90
- 2023: 117.13
- 2022: 0
- 2021: 14.91
- 2020: 12.96
The decline in Jubilant Pharmova Ltd Price to Earnings Ratio indicates improving financial efficiency or better earnings growth.
What Jubilant Pharmova Ltd Price to Earnings Ratio Indicates for Investors
The Jubilant Pharmova Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Jubilant Pharmova Ltd Price to Earnings Ratio Analysis Summary
The Jubilant Pharmova Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Jubilant Pharmova Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Jubilant Pharmova Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.